Watson Pharmaceuticals (WPI) receives final FDA approval for its lidocaine topical patch 5%, the...
Watson Pharmaceuticals (WPI) receives final FDA approval for its lidocaine topical patch 5%, the generic equivalent to Endo Health Solutions's (ENDP) Lidoderm. The drug developer plans to launch the product in September, pursuant with its settlement agreement with ENDP and believes that under Hatch Waxman rules, it will be entitled to 180 days of marketing exclusivity. WPI +0.2%, ENDP -3.7% AH.
From other sites
Video at CNBC.com (Aug 6, 2015)
Video at CNBC.com (Jul 27, 2015)
at CNBC.com (Feb 18, 2015)
at CNBC.com (Feb 10, 2015)
at CNBC.com (Feb 5, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs